Navigation Links
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Date:10/21/2008

"http://www.avidbio.com" target="_new">http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will experience delays or difficulties in enrolling patients in the study, the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy, and the risk that the results from this trial will not be consistent with the results of prior trials or preclinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... England , August 31, 2015 /PRNewswire/ ... 51-jährige Wartezeit   einer Frau   für chirurgische   ... Alter von 7-90   werden für eine ... Programm soll 1200 Frauen behandeln und die Anzahl ausgebildeter ... Astellas gab heute bekannt, dass  Action ...
(Date:8/28/2015)... 28, 2015 According to a ... Cryogenic Storage Systems, Thawing Equipment, Alarms), by Biospecimen (Human ... Trials), End User - Global Forecast to 2020", published ... reach USD 3,731.03 Million by 2020 from USD 2,150.48 ... between 2015 and 2020. Browse 74 ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Gardner, has organized and will present a session on chemical spectroscopic imaging at ... conference and exposition is Asia’s largest analytical and scientific instruments show which will ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... and orthopedic surgeon, Wade McKenna, DO, announced today that the use of sterile, ... resulted in complete healing of an otherwise non-healing surgical knee wound. , The ...
Breaking Biology Technology:Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4
... warm business climate,and appealing lifestyle, Florida is fast ... Statewide, Florida,s high-tech industries added 10,900 net jobs ... to Florida Cybercities,2007, a recent report by the ... data available. With a 4 percent growth ...
... N.J., Nov. 15 At a ... Wyeth (NYSE: WYE ), held ... per share on the outstanding shares ... January 2, 2008 to stockholders of ...
... Inc. (OTC Bulletin Board: AIDA) today announced that it,has ... 30, 2007. Net,revenues totaled $7,373,770 for the quarter ended ... 2006. Gross profit decreased by 2.66% due to an,increase ... Aida,s,transfusion and injection forms of etimicin sulfate increased markedly.,Gross ...
Cached Biology Technology:Florida's Technology Sector Attracting Skilled Workers Needing Homes 2Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Saudi Arabia Biomedical Sensors Market - ... offering. The Saudi Arabia Biomedical Sensors ... a CAGR of 3.64% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... In our not-so-distant evolutionary past, stress often meant ... so part of our body,s stress response is ... Medicine Partnership Unit (MMPU), a collaboration between the ... and the University of Heidelberg Medical Centre, have ...
... in the long-standing arms race between the flowering plant ... Duke University researchers have found that the little mustard ... prepare for the greatest onslaught of infectious spores released by ... time of day it is and change their activities accordingly, ...
... PORTLAND, Ore. -- The pediatric cardiac team at Oregon ... first in the region and one of a handful ... without open-heart surgery. To date, four patients have ... Adult Congenital Cardiac Catheterization Lab. All reported immediate improvement ...
Cached Biology News:Blood-clotting protein linked to cancer and septicemia 2Blood-clotting protein linked to cancer and septicemia 3Plant's immune defense revs up for the morning attack 2Plant's immune defense revs up for the morning attack 3OHSU fixes complex heart problems without open-heart surgery 2
RABBIT ANTI HUMAN APP (KP1 DOMAIN) Immunogen: Synthetic peptide composed of amino acids 292-312 from the KPI domain of human APP....
... The Light Diagnostics Cytomegalovirus (CMV) pp65 ... the qualitative identification of lower matrix protein ... leukocytes. Kit Components: ... 5122) One bottle containing 220 mL of ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
Biology Products: